SCHEMBL770409

SCHEMBL770409

CC(C)(C)NC(=O)NCCC(=O)N1CCCC2CCCCC21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 5/20 0.40
CYP2D6 P10635 5/20 0.40
KCNH2 Q12809 5/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD11B1 P28845 1/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
DPP4 P27487 4/20 0.38
OPRD1 P41143 3/20 0.37
MAPT P10636 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRK1 P41145 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771348 0.91 DPP4 (0.40) CACNA1HCYP2D6KCNH2DRD2DRD4
SCHEMBL770359 0.88 DRD2 (0.37) DRD2DRD4NPC1RAB9ASMN1; SMN2
SCHEMBL770411 0.84 NPC1 (0.43) CACNA1HCYP2D6KCNH2NPC1RAB9A
SCHEMBL770027 0.83 DRD2 (0.39) DRD2DRD4NPC1RAB9ASMN1; SMN2
SCHEMBL770987 0.82 NPSR1 (0.44) DPP4
SCHEMBL801893 0.81 EPHX1 (0.46) DRD2DRD4NPC1RAB9ASMN1; SMN2
SCHEMBL769965 0.81 NPC1 (0.50) DRD2DRD4NPC1RAB9ASMN1; SMN2
SCHEMBL771679 0.81 NPC1 (0.47) DRD2DRD4NPC1RAB9ASMN1; SMN2
SCHEMBL771009 0.81 EPHX2 (0.51) NPC1RAB9ASMN1; SMN2
SCHEMBL770636 0.81 EPHX2 (0.51) NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 CACNA1H 3471/4885CYP2D6 395/4885KCNH2 4431/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 CACNA1H 3464/4885CYP2D6 394/4885KCNH2 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.